Page 6,226«..1020..6,2256,2266,2276,228..6,2406,250..»

Kaplan Headache Center and the Stroke Treatment

Posted: Published on November 9th, 2012

Kaplan Headache Center and the Stroke Treatment Prevention Center - Clifton Park, NY Kaplan Headache Center and the Stroke Treatment Prevention Center 518-388-9900 http://www.yellowbook.com eugene-kaplan-md-erpxg8zma-5183889900.flvFrom:yellowbookViews:0 0ratingsTime:00:36More inHowto Style Link: Kaplan Headache Center and the Stroke Treatment … Continue reading →

Comments Off on Kaplan Headache Center and the Stroke Treatment

RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of PRADAX® for stroke …

Posted: Published on November 9th, 2012

Presented at AHA's Scientific Sessions 2012, first long-term results from the RELY-ABLE study demonstrate that advantages of PRADAX (dabigatran etexilate) treatment are maintained over more than four years PRADAX is the first and only novel oral anticoagulant supported by long-term clinical data Sustained benefits for both doses allow for persistent brain protection and tailored treatment according to patient needs BURLINGTON, ON, Nov. 8, 2012 /CNW/ - Data from the *RELY-ABLE study have provided additional data to support the long-term safety profile and efficacy of PRADAX (dabigatran etexilate) for stroke prevention in patients with non-valvular atrial fibrillation (AF). **1 The new long-term results presented at the American Heart Association's (AHA) Scientific Sessions, are highly consistent with the findings from the landmark RE-LY trial, the basis for the approval of PRADAX in countries all over the world. The rates of stroke and hemorrhage observed during the 2.3 years of blinded follow-up in RELY-ABLE correspond to the initial RE-LY results, supporting the benefit of both doses of PRADAX for tailored brain protection.1-3 The combined data from RE-LY and RELY-ABLE equates to over four years of experience and provides the most comprehensive evaluation of the benefits and safety of any novel oral anticoagulant for … Continue reading →

Comments Off on RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of PRADAX® for stroke …

Radisphere Helps Bring New Imaging Procedure to California’s Adventist Medical Center – Hanford to Aid in Stroke …

Posted: Published on November 9th, 2012

CLEVELAND--(BUSINESS WIRE)-- Radisphere (www.radispheregroup.com), the largest and fastest-growing national radiology group in the United States, today announced that it has helped implement a new imaging procedure for the medical staff at Adventist Medical Center - Hanford in California. The procedure, known as a computed tomography (CT) brain perfusion exam, can provide better diagnostic information for suspected stroke patients. Sanjeev Athale, M.D., who is the Onsite Medical Director of Radiology at Adventist Medical Center - Hanford and employed locally by Radisphere, was instrumental in bringing this new procedure to Adventist Health / Central Valley Network. We are excited to have this procedure, usually only offered at hospitals in major urban settings, available in the Central Valley, said Kendall Fults, R.N. and Senior Vice President of Network Operations at Adventist Health. It is important to have strategic partners like Radisphere to help us provide quality services so the medical staff can offer faster comprehensive patient care. A CT brain perfusion exam can quickly evaluate blood flow in the brain and help physicians see if a patient is about to have a stroke. The exam measures blood flow, blood volume, and the time required for blood to pass through tissue in order to … Continue reading →

Comments Off on Radisphere Helps Bring New Imaging Procedure to California’s Adventist Medical Center – Hanford to Aid in Stroke …

Swedish Medical Center in Englewood has new stroke treatment

Posted: Published on November 9th, 2012

In past years, clot-busting medication was the primary treatment for an ischemic stroke, where a clot cuts off blood supply to part of the brain. But Swedish Medical Center is using new technology that, in many cases, can reach and remove the clot. Our center treats 20 to 30 stroke patients a month, said Dr. Donald Frei, the neurointerventional radiologist at Swedish. We are one of 20 hospitals doing a pilot program study on an improved catheter system that is inserted in the blocked artery. The innovation is the separator that is inserted into the catheter and through the clot. Then the separator then grabs the clot, drawing it back into the catheter, where suction removes it from the artery. The device is called the Penumbra MAX System Reperfusion Catheter, and Frei said the device is important because, in stroke treatment, time is everything. The saying in stroke treatment is that time is brain, he said. That is because cutting off blood supply to any part of the brain means 30,000 brain cells die every second. Swedish is the only hospital in the Rocky Mountain area using the new technology. Frei said there are 800,000 strokes a year in the … Continue reading →

Comments Off on Swedish Medical Center in Englewood has new stroke treatment

Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release

Posted: Published on November 9th, 2012

SUNNYVALE, Calif., Nov. 7, 2012 /PRNewswire/ --Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today updated shareholders on the timing of the final data set from its grant from the Michael J. Fox Foundation being released to the marketplace. The Company expects to have the data set available in December. Upon completion of the data analysis correlate of the positive behavioural animal data for MANF previously reported with histology data confirming re-innervation of the striatum due to MANF delivery to the substantia nigra, the Michael J. Fox Foundation will consider funding additional studies to advance MANF as a disease-modifying treatment for Parkinson's disease. About Amarantus BioSciences, Inc. Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release

Depomed Reports Top Line Data for Phase 2 Study in Parkinson's Disease

Posted: Published on November 9th, 2012

MENLO PARK, Calif., Nov. 7, 2012 /PRNewswire/ --Depomed, Inc. (DEPO) today announced top line results from a Phase 2 clinical trial of DM-1992, Depomed's investigative novel gastric-retentive, extended-release formulation of carbidopa/levodopa, in patients with advanced Parkinson's disease with motor fluctuations. Phase 2 Study Design and ResultsThe trial was a randomized, active-controlled, open-label, crossover study evaluating DM-1992 dosed twice daily against a generic version of immediate-release carbidopa/levodopa (IR CD/LD) dosed as needed (mean daily dosing frequency = 4.8).34 patients with advanced Parkinson's disease with motor fluctuations enrolled in the study at eight U.S. clinical centers.All enrolled patients completed the study. Baseline measurements were established over a three-day patient self-assessment period during which patients were maintained on existing Parkinson's medications.DM-1992 and IR CD/LD were each administered over a ten-day period that included a six-day dose optimization period, followed by a three-day patient self-assessment period and one in-clinic day for clinician evaluation and pharmacokinetic measurements. The primary endpoint for the study is change in percent "off" time during waking hours, as measured by patient self-assessment during the treatment period relative to the baseline period.Patients' mean baseline "off" time during waking hours was 5.4 hours per day (32.5%), compared to 4.5 hours (27.2%) during … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Depomed Reports Top Line Data for Phase 2 Study in Parkinson's Disease

Your help sees Hope For Georgia hit £20,000 target

Posted: Published on November 9th, 2012

Buy photos Georgia with mum Natalie at Georgia's second birthday party. s BROMSGROVE two-year-old Georgia Almquest who has cerebral palsy has had the best early Christmas present she could have hoped for - 20,000 to send her for specialist stem cell treatment. The organisers of the Hope For Georgia campaign revealed this week that the target amount has now been reached and the toddler will be having the operation in the new year. The cerebral palsy means Georgia had spastisity in all four of her limbs and cannot hold her head up, sit or crawl. The procedure offers her the only chance she has of being able to walk. Georgia's mum Natalie told The Standard: "I want to say a massive thank you to everyone who has helped, contributed and organised events - it has been fantastic. "This has been the best present we could ever have wished for." She said, when the campaign started, she thought it would take over a year to accumulate the funds, but the 20,000 has been raised in just over two months. Amanda Naughton, who was the founder of the campaign, said: "I have been absolutely blown away by the compassion of family, friends … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Your help sees Hope For Georgia hit £20,000 target

MRI and EEG could identify children at risk for epilepsy after febrile seizures

Posted: Published on November 9th, 2012

ScienceDaily (Nov. 7, 2012) Seizures during childhood fever are usually benign, but when prolonged, they can foreshadow an increased risk of epilepsy later in life. Now a study funded by the National Institutes of Health suggests that brain imaging and recordings of brain activity could help identify the children at highest risk. The study reveals that within days of a prolonged fever-related seizure, some children have signs of acute brain injury, abnormal brain anatomy, altered brain activity, or a combination. "Our goal has been to develop biomarkers that will tell us whether or not a particular child is at risk for epilepsy. This could in turn help us develop strategies to prevent the disorder," said study investigator Shlomo Shinnar, M.D., Ph.D. Dr. Shinnar is a professor of neurology, pediatrics and epidemiology and the Hyman Climenko Professor of Neuroscience Research at Montefiore Medical Center, Albert Einstein College of Medicine, New York City. Seizures that occur during the course of a high fever, known as febrile seizures, affect 3 to 4 percent of all children. Most such children recover rapidly and do not suffer long-term health consequences. However, having one or more prolonged febrile seizures in childhood is known to increase the … Continue reading →

Posted in Brain Injury Treatment | Comments Off on MRI and EEG could identify children at risk for epilepsy after febrile seizures

UM/Jackson Rehab Medicine awarded prestigious grant

Posted: Published on November 9th, 2012

The rehabilitation medicine team at the University of Miami Miller School of Medicine, in conjunction with Jackson Rehabilitation Hospital, has been awarded a federal Traumatic Brain Injury Model Systems (TBIMS) grant of more than $2 million. Funded by the National Institute on Disability and Rehabilitation Research (NIDRR), the five-year grant will enhance rehabilitation services and research aimed at meeting the special needs of individuals with brain injuries as they progress through the clinical continuum, from emergency care to rehabilitation and community reentry. The highly competitive selection process for the prestigious U.S. Department of Education funding resulted in UM/Jackson being the only Florida award recipient, making it one of just 16 sites nationally that were awarded the grant. Last year, UM/Jackson also was awarded a Spinal Cord Injury Model Systems program grant, which is directed by Diana Cardenas, MD, MHA, chair of rehabilitation medicine at the Miller School of Medicine and chief of rehabilitation at Jackson Memorial Hospital. This will make us one of a select group of rehabilitation medicine departments in the country that have both a spinal cord injury and a traumatic brain injury model system program, Cardenas said. The centers selected for this grant provide a multidisciplinary system … Continue reading →

Posted in Brain Injury Treatment | Comments Off on UM/Jackson Rehab Medicine awarded prestigious grant

InfraScan Launches International Sales of its Ruggedized Handheld Brain Hematoma Detector

Posted: Published on November 9th, 2012

Sales of the Infrascanner Model 2000, a ruggedized handheld brain hematoma detector, are launched at MEDICA trade fair in Dusseldorf, Germany Philadelphia, PA (PRWEB) November 08, 2012 The Infrascanner Model 2000 is a handheld device that uses Near-Infrared (NIR) technology to detect intracranial bleeding, identifying those patients who would most benefit from immediate referral to a CT scan and neurosurgical intervention. In the triage of head trauma patients, the Infrascanner can identify patients most likely to have intracranial bleeding. The Infrascanner Model 2000 is based on the Infrascanner Model 1000, following the specifications of the US Marine Corps. The US Navy and Marines supported the development of the technology. The improvements in the Infrascanner Model 2000 include: The Infrascanner is designed to assist first responders and emergency room personnel in identifying life threatening brain hematomas, allowing expedient assessment of patients and potentially facilitating life-saving treatment. An estimated 1.5 million individuals seek medical treatment for head trauma in the U.S. each year, and a total of 10 million individuals seek head trauma treatment annually worldwide. Intracranial hematomas resulting from a traumatic brain injury are life-threatening and have been reported to occur as the primary injury in 40% of patients with severe … Continue reading →

Posted in Brain Injury Treatment | Comments Off on InfraScan Launches International Sales of its Ruggedized Handheld Brain Hematoma Detector

Page 6,226«..1020..6,2256,2266,2276,228..6,2406,250..»